OOIR: Observatory of International Research

Papers

(The TQCC of Current Opinion in Virology is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-07-01 to 2025-07-01.)

Article	Citations
Editorial Board	184
Colonization of peripheral ganglia by herpes simplex virus type 1 and 2	143
Inhaled aerosol viral-vectored vaccines against tuberculosis	116
Mutational escape from cellular immunity in viral hepatitis: variations on a theme	88
Interfering with SARS-CoV-2: are interferons friends or foes in COVID-19?	87
Adenoviral-vectored next-generation respiratory mucosal vaccines against COVID-19	74
Transmission patterns of hepatitis E virus	69
The enigmatic roles of Anelloviridae and Redondoviridae in humans	67
Hepatitis-B virus: replication cycle, targets, and antiviral approaches	65
Monoclonal antibodies against rabies: current uses in prophylaxis and in therapy	64
Editorial Board	63
Editorial overview: Viral pathogenesis	55
Virus–host protein interactions as footprints of human cytomegalovirus replication	49
Structural basis for neutralization of enterovirus	49
Human placental models for studying viral infections	49
Viral–host interactions during splicing and nuclear export of influenza virus mRNAs	46
Editorial overview: Mechanisms in the molecular interactions of plants with viruses and viroids	45
Editorial Board	44
The journey of herpesvirus capsids and genomes to the host cell nucleus	42
Paramyxoviruses from bats: changes in receptor specificity and their role in host adaptation	39
Recent progress in development of monoclonal antibodies against human cytomegalovirus	39
Hepatitis C virus envelope protein dynamics and the link to hypervariable region 1	39
Time to ‘Mind the Gap’ in novel small molecule drug discovery for direct-acting antivirals for SARS-CoV-2	39
Emerging technologies in the study of the virome	36
The two faces of oligoadenylate synthetase-like: effective antiviral protein and negative regulator of innate immunity	35

New preventive strategies for respiratory syncytial virus infection in children	34
Shopping for phages? Unpacking design rules for therapeutic phage cocktails	34
Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection	33
A complex immune communication between eicosanoids and pulmonary macrophages	32
Epigenetic control of the Epstein-Barr lifecycle	31
The enigma of picobirnaviruses: viruses of animals, fungi, or bacteria?	31
Engineering therapeutic phages for enhanced antibacterial efficacy	30
A review of broadly protective monoclonal antibodies to treat Ebola virus disease	30
Mitigation of evolved bacterial resistance to phage therapy	28
Platelets in the pathogenesis of flavivirus disease	28
Editorial Board	27
Perspective on taxonomic classification of uncultivated viruses	27
Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome: challenges and opportunities	26
Role of mucosal-associated invariant T cells in coronavirus disease 2019 vaccine immunogenicity	26
Asymmetry in icosahedral viruses	26
When good turns bad: how viruses exploit innate immunity factors	26
Retasking of canonical antiviral factors into proviral effectors	26
Does arbovirus emergence in humans require adaptation to domestic mosquitoes?	25
Tissue-resident memory T cells in protective immunity to influenza virus	25
Hemagglutinin stability as a key determinant of influenza A virus transmission via air	25
Therapeutic vaccination strategies against EBOV by rVSV-EBOV-GP: the role of innate immunity	24
Modeling zoonotic and vector-borne viruses	24
Mechanisms of HCV resistance to broadly neutralizing antibodies	24
Role of the viral polymerase during adaptation of influenza A viruses to new hosts	23
Antibody landscapes of SARS-CoV-2 can reveal novel vaccine and diagnostic targets	23
Diagnosis and monitoring of virus-associated cancer using cell-free DNA	23
Oncogenic Animal Herpesviruses	23
Immune responses to human respiratory coronaviruses infection in mouse models	22
Nucleoside analogs for management of respiratory virus infections: mechanism of action and clinical efficacy	22
MEK inhibitors as novel host-targeted antivirals with a dual-benefit mode of action against hyperinflammatory respiratory viral diseases	22
MicroRNA-mediated control of Epstein–Barr virus infection and potential diagnostic and therapeutic implications	22
The virome of vector mosquitoes	21
Deimmunization of flagellin adjuvant for clinical application	21
Advances in human monoclonal antibody therapy for HBV infection	20
Broadly neutralizing antibodies against COVID-19	20
The impact of high-resolution structural data on stemming the COVID-19 pandemic	20
The biology of papillomavirus PDZ associations: what do they offer papillomaviruses?	20
Antigenic evolution of SARS coronavirus 2	20
Bat virome research: the past, the present and the future	20
Editorial overview	20